Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th Internation...
01 Diciembre 2015 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, announced that a late breaking abstract
describing results from the ACE-083 Phase 1 clinical trial has been
selected for an oral plenary presentation in the Late Breaking
Clinical Trials Session at the 8th International Conference on
Cachexia, Sarcopenia, and Muscle Wasting. The conference will take
place in Paris, France, December 4-6, 2015.
ACE-083 has been designed to increase muscle mass and strength
selectively in the muscles into which the drug is
administered. Acceleron is developing ACE-083 for diseases
such as facioscapulohumeral and certain other forms of muscular
dystrophy in which improved muscle strength in a specific set of
muscles may provide a clinical benefit.
Oral
Presentation
Date: Saturday, December 5 Title:
A Phase 1 Dose Escalation Study of
ACE-083 in Healthy Volunteers: Preliminary Results for a Locally
Acting Muscle Therapeutic (Abstract #1-72)
Session: 55. Clinical science track: Late breaking clinical trials
& trial updates Time: 4:30 - 6:30 PM CET Location: Novotel
Paris Tour Eiffel, Hall A
Poster
Presentation
Date: Sunday, December 6 Title:
A Phase 1 Dose Escalation Study of
ACE-083 in Healthy Volunteers: Preliminary Results for a Locally
Acting Muscle Therapeutic (Abstract #1-72)
Session: 16. Muscle wasting, sarcopenia, myopenia VI Time: 9:35 -
10:25 AM CET Location: Novotel Paris Tour Eiffel, Poster Area
The clinical presentation and poster will be available on
Acceleron’s website (www.acceleronpharma.com) under the
“Publications” tab when presented at the conference.
About ACE-083
ACE-083 is a therapeutic candidate that acts as a ligand trap
for members in the Transforming Growth Factor-Beta (TGF-β)
superfamily involved in the regulation of muscle mass and strength.
ACE-083 has been designed to increase muscle mass and strength
selectively in the muscles into which the drug is
administered. Acceleron is developing ACE-083 for diseases in
which improved muscle strength in a specific set of muscles may
provide a clinical benefit, such as facioscapulohumeral and certain
other forms of muscular dystrophy. ACE-083 is currently in a phase
1 clinical trial in healthy volunteers. For additional information
on this clinical trial, please visit www.clinicaltrials.gov,
identifier NCT02257489.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the
Transforming Growth Factor-Beta (TGF-β) protein superfamily, a
large and diverse group of molecules that are key regulators in the
growth and repair of tissues throughout the human body, and in
targeting these pathways to develop important new medicines.
Acceleron has built a highly productive R&D platform that has
generated innovative clinical and preclinical therapeutic
candidates with novel mechanisms of action. These therapeutic
candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151201005548/en/
Acceleron Pharma Inc.Todd James, 617-649-9393Senior Director,
Corporate CommunicationsorMedia:BMC Communications LLCBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024